Jiangxi Institute of Biological Products: Supporting Poverty Alleviation, Education, and More Importantly, Determination

2017-01-12

Regulations on Reporting and Monitoring of Adverse Drug Reactions

"Measures for the Reporting and Monitoring of Adverse Drug Reactions" (Ministry of Health Order No. 81) issued on May 4, 2011, Ministry of Health of the People's Republic of China Order No. 81. The "Measures for the Reporting and Monitoring of Adverse Drug Reactions" were reviewed and approved at the Ministry of Health executive meeting on December 13, 2010, and are hereby promulgated, effective from July 1, 2011. Minister Chen Zhu May 4, 2011 Adverse Drug Reaction Reporting and Monitoring

2015-12-13

Drug Recall Management Measures

Order No. 29 of the State Food and Drug Administration: The "Drug Recall Management Measures" was reviewed and approved by the State Food and Drug Administration's bureau meeting on December 6, 2007, and is hereby promulgated and shall come into effect from the date of promulgation. Director Shao Mingli December 10, 2007 Drug Recall Management Measures Chapter 1 General Provisions Article 1 To strengthen drug safety supervision and ensure public medication safety, in accordance with the "Drug Administration Law of the People's Republic of China," the "Implementation Regulations of the Drug Administration Law of the People's Republic of China," and the "State Council's Special Regulations on Strengthening the Supervision and Administration of Food and Other Product Safety"

2015-12-13

Good Manufacturing Practice for Pharmaceutical Products 2010 Revision

Good Manufacturing Practice for Pharmaceutical Products (2010 Revision) (Ministry of Health Order No. 79) Issued on February 12, 2011 Ministry of Health of the People's Republic of China Order No. 79 The "Good Manufacturing Practice for Pharmaceutical Products (2010 Revision)" was reviewed and approved by the Ministry of Health Executive Meeting on October 19, 2010, and is hereby promulgated, effective from March 1, 2011. Minister Chen Zhu January 17, 2011 Chapter 1 General Provisions Article 1 To standardize the quality management of pharmaceutical production, in accordance with the "Drug Administration Law of the People's Republic of China" and the "China

2015-12-13

Good Supply Practice for Pharmaceutical Products

Good Manufacturing Practice for Pharmaceutical Operation (Ministry of Health Order No. 90) National Health and Family Planning Commission of the People's Republic of China www.moh.gov.cn Order No. 90 The "Good Manufacturing Practice for Pharmaceutical Operation" was reviewed and approved by the Ministry of Health's executive meeting on November 6, 2012, and is hereby promulgated, effective from June 1, 2013. Minister Chen Zhu January 22, 2013 Good Manufacturing Practice for Pharmaceutical Operation Chapter 1 General Provisions Article 1 To strengthen the quality management of pharmaceutical operation, regulate pharmaceutical operation behavior, and ensure the safety and effectiveness of human medication, according to

2015-12-13

Drug Administration Law of the People's Republic of China

(Adopted at the 7th meeting of the Standing Committee of the 6th National People's Congress on September 20, 1984, amended at the 20th meeting of the Standing Committee of the 9th National People's Congress on February 28, 2001, revised according to the Decision on Amending Seven Laws Including the <Marine Environmental Protection Law of the People's Republic of China> at the 6th meeting of the Standing Committee of the 12th National People's Congress on December 28, 2013, and the Decision on Amending the <Drug Administration Law of the People's Republic of China> at the 14th meeting of the Standing Committee of the 12th National People's Congress on April 24, 2015) First

2015-12-13

相约女人节，踏青庐陵文化态园 ---2012年国际三八妇女节报道

为纪念“三•八”国际劳动妇女节102周年，让全体女职工过一个健康、和谐、快乐、温馨、难忘而有意义的节日，江西生物制品研究所不仅给在职女职工发放节日津贴，并派出了由公司工会主席刘冰为领队的10余人女职工参加了吉安市直工会在市庐陵文化生态园举办市直机关、企业女职工游园活动，大家不仅兴趣昂然的游园还积极参加了市直工会举行的趣味游戏活动，如套圈、跳绳、抛接乒乓球等，并有8人荣获优胜奖。 　　本次“三八”妇

2015-12-13

Eight types of biological products will be more strictly regulated next year

According to the National Medical Products Administration, starting from January 1 next year, China will implement a batch release system for eight types of biological products, including human albumin, recombinant hepatitis B vaccine, live attenuated measles vaccine, BCG vaccine, oral live attenuated poliovirus vaccine, and the combined adsorbed pertussis, diphtheria, and tetanus vaccine. According to relevant sources, this is an important step for China's biological product management standards to align with international practices. Batch release of biological products refers to the national authority's inspection and approval of each batch of vaccines, blood products, in vitro biological diagnostic reagents used for blood screening, and other specified biological products before they are released to the market or imported.

2014-10-06

The development momentum of biotechnology in our country is unstoppable

With the rapid development of science and technology, the bioengineering and new drug markets have become exceptionally active, especially in recent years as China's pharmaceutical market gradually integrates with the global market. The biopharmaceutical industry has rapidly emerged, and under stock market speculation, the manufacturing industry, primarily based on chemical drugs, is quickly shifting towards bioengineering technology products. In today's slow progress of chemical innovative drug development, the globalization characteristics of bioengineered drugs have become increasingly prominent and have attracted more attention. Gene products are emerging like mushrooms after rain. Biotechnological drugs refer to proteins, antibodies, or other products developed using DNA recombinant technology, monoclonal antibody technology, or other new biotechnologies.

2014-10-06

Chinese Medicine: The Patent Dilemma Under the "Generic" System

As the third year after joining the "WTO" organization, some have called this year the beginning of the "post-WTO transition period." After experiencing the adjustment period of the first two years, deep-seated issues in China's integration with the international community have gradually emerged, among which intellectual property has increasingly become an unavoidable focal issue. This year, the dispute between multinational pharmaceutical giant Pfizer and more than ten domestic pharmaceutical companies over Viagra is seen by industry insiders as a landmark event revealing the long-standing intellectual property bottleneck troubling China's pharmaceutical industry; in fact, it is an intellectual property battle. It is understood that Pfizer underwent a 10-year research process to invent Viagra.

2014-10-06